NMTC:NASDAQNeuroOne Medical Technologies Corporation analysis

NeuroOne Medical Technologies Corporation trades at $1.12, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Over a rolling month the price has lost 43.4%. Relative strength is 35.1 — approaching oversold — and the MACD signal is bullish. The recent range runs from support at $0.9620 up to resistance at $1.58.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 548.8% above today's level. Revenue is growing at 16.3% on a -59.7% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 85.0%, a beta of 0.77 and a maximum drawdown of 83.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.